At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Aug 3, 2026 at 05:00 ET
BioNTech announced the appointment of Guido Oelkers, Ph.D., as the new CEO, effective by February 1, 2027, succeeding co-founder Prof. Ugur Sahin. Oelkers joins from Sobi, where he more than quadrupled revenues over nine years. This leadership transition is a routine succession event for a company in a pivotal phase, with no immediate financial impact or change to the pipeline strategy.
- Guido Oelkers appointed as CEO, effective by February 1, 2027
- Oelkers succeeds Prof. Ugur Sahin, who will support the transition
- Oelkers previously served as CEO of Sobi, where he more than quadrupled revenues from 2017 to 2026
- Prof. Özlem Türeci will transition to lead a new independent company with Prof. Sahin
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access